VALIDATING THE RESULTS OF A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) IN MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Hatswell, A. [1 ]
Batteson, R. [1 ]
Hook, E. [1 ]
Wheat, H. [1 ]
Vioix, H. [2 ]
McLean, T. [3 ]
Alexopoulos, S. [3 ]
Baijal, S. [4 ]
机构：
[1] Delta Hat Ltd, Nottingham, England
[2] Merck Healthcare KGaA, Darmstadt, Germany
[3] Merck Serono Ltd, Feltham, England
[4] Univ Hosp Birmingham NHS Trust, Birmingham, W Midlands, England
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO23
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [41] Tepotinib in patients with MET exon 14 (METex14) skipping advanced NSCLC: Updated efficacy results from VISION cohort A
    Sakai, Hiroshi
    Morise, Masahiro
    Felip, Enriqueta
    Veillon, Remi
    Garassino, Marina Chiara
    Raskin, Jo
    Viteri, Santiago
    Mazieres, Julien
    Cortot, Alexis B.
    Smit, Egbert
    Thomas, Michael
    Cho, Byoung Chul
    Conte, Pierfranco
    Yang, James Chih-Hsin
    Chen, Yuh-Min
    Park, Keunchil
    Gottfried, Maya
    Britschgi, Christian
    Le, Xiuning
    Paik, Paul
    ANNALS OF ONCOLOGY, 2021, 32 : S290 - S290
  • [42] Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION)
    Morise, Masahiro
    Sakai, Hiroshi
    Kato, Terufumi
    Matsumoto, Shingo
    Kumagai, Toru
    Sakamoto, Tomohiro
    Tokito, Takaaki
    Atagi, Shinji
    Kozuki, Toshiyuki
    Takeoka, Hiroaki
    Chikamori, Kenichi
    Shinagawa, Naofumi
    Tanaka, Hiroshi
    Hirashima, Tomonori
    Eggleton, S. Peter
    Bruns, Rolf
    Otto, Gordon
    Paik, Paul
    ANNALS OF ONCOLOGY, 2022, 33 : S475 - S475
  • [43] Intracranial Activity of Tepotinib in Patients (pts) With MET exon 14 (METex14) Skipping NSCLC Enrolled in VISION
    Bestvina, C. M.
    Patel, J. D.
    Le, X.
    Veillon, R.
    Anderson, I.
    Demedts, I.
    Garassino, M.
    Mazieres, J.
    Morise, M.
    Smit, E.
    Eggleton, S. P.
    O'Brate, A.
    Otto, G.
    Bruns, R.
    Schumacher, K. M.
    Paik, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (02): : E14 - E15
  • [44] Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.
    Minne, Rachel
    Luo, Natalie
    Traynor, Anne M.
    Huang, Minxuan
    De Tullio, Luisina
    Godden, Jen
    Stoppler, Melissa Conrad
    Kimple, Randall J.
    Baschnagel, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] MODELING THE COST-EFFECTIVENESS IN A SUBPOPULATION: TEPOTINIB VERSUS CHEMOIMMUNOTHERAPY (C plus IO) IN UNTREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    Batteson, R.
    Vioix, H.
    Wheat, H.
    Battershill, W.
    VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [46] Characterization of MET exon 14 skipping in Chinese non-small cell lung cancer (NSCLC) patients.
    Zhang, Baihua
    Xia, Yu
    Zhang, Jiujin
    Yu, Jin
    Chen, Min
    Yao, Wei
    Zhao, Juan
    He, Jiqiang
    Mok, Tony S. K.
    Wang, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Clinical outcomes in advanced Non-Small Cell Lung Cancer (NSCLC) with MET exon 14 skipping mutation
    Smith, Miles
    Carter, Mat
    Woodhouse, Laura
    Adderley, Helen
    Morrissey, George
    Brown, Kate
    Nicola, Pantelis
    Weaver, Jamie
    Califano, Raffaele
    Summers, Yvonne
    Cove-Smith, Laura
    Hughes, Sarah
    Taylor, Paul
    Blackhall, Fiona
    Lindsay, Colin R.
    LUNG CANCER, 2024, 190
  • [48] Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
    Le, X.
    Martinalbo, J.
    Holynskyj, A.
    Rhodes, W. C.
    Wu, W-H.
    Kim, J.
    Pretre, V.
    Ye, F.
    Morrissette, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S988 - S988
  • [49] Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A
    Mazieres, J.
    Paik, P. K.
    Felip, E.
    Veillon, R.
    Sakai, H.
    Cortot, A. B.
    Viteri, S.
    Garassino, M. C.
    Van Meerbeeck, J. P.
    Raskin, J.
    Thomas, M.
    Morise, M.
    Cho, B. C.
    Conte, P.
    Bruns, R.
    Demuth, T.
    Schumacher, K. M.
    Le, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S828 - S829
  • [50] A PROPENSITY SCORE-BASED COMPARISON OF TEPOTINIB VERSUS IMMUNOTHERAPY WITH/WITHOUT CHEMOTHERAPY, USING REAL-WORLD DATA IN PREVIOUSLY UNTREATED MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)
    Hook, E.
    Batteson, R.
    Christopoulos, P.
    Guisier, F.
    Ekman, S.
    Hatswell, A.
    Vioix, H.
    VALUE IN HEALTH, 2023, 26 (12) : S44 - S44
12345